LA JOLLA, Calif.–(BUSINESS WIRE)– #ANRE–Arialys Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
